Repro Total Stockholder Equity from 2010 to 2024
| KRMD Stock | USD 3.98 0.06 1.49% |
Total Stockholder Equity | First Reported 2000-06-30 | Previous Quarter 18.7 M | Current Value 17.7 M | Quarterly Volatility 11.8 M |
Check Repro Med financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Repro Med's main balance sheet or income statement drivers, such as Depreciation And Amortization of 913.9 K, Interest Expense of 159.1 K or Total Revenue of 29.9 M, as well as many indicators such as Price To Sales Ratio of 2.26, Dividend Yield of 0.0031 or PTB Ratio of 5.79. Repro financial statements analysis is a perfect complement when working with Repro Med Valuation or Volatility modules.
Repro | Total Stockholder Equity |
Latest Repro Med's Total Stockholder Equity Growth Pattern
Below is the plot of the Total Stockholder Equity of Repro Med Systems over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Repro Med's Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Repro Med's overall financial position and show how it may be relating to other accounts over time.
| Total Stockholder Equity | 10 Years Trend |
|
Total Stockholder Equity |
| Timeline |
Repro Total Stockholder Equity Regression Statistics
| Arithmetic Mean | 13,826,716 | |
| Geometric Mean | 9,036,465 | |
| Coefficient Of Variation | 88.22 | |
| Mean Deviation | 10,210,086 | |
| Median | 7,669,730 | |
| Standard Deviation | 12,198,526 | |
| Sample Variance | 148.8T | |
| Range | 35.8M | |
| R-Value | 0.79 | |
| Mean Square Error | 59.3T | |
| R-Squared | 0.63 | |
| Significance | 0.0004 | |
| Slope | 2,164,527 | |
| Total Sum of Squares | 2083.3T |
Repro Total Stockholder Equity History
About Repro Med Financial Statements
Repro Med stakeholders use historical fundamental indicators, such as Repro Med's Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Repro Med investors may analyze each financial statement separately, they are all interrelated. For example, changes in Repro Med's assets and liabilities are reflected in the revenues and expenses on Repro Med's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Repro Med Systems. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Stockholder Equity | 20.4 M | 21.4 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Repro Med Systems is a strong investment it is important to analyze Repro Med's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Repro Med's future performance. For an informed investment choice regarding Repro Stock, refer to the following important reports:Check out the analysis of Repro Med Correlation against competitors. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repro Med. If investors know Repro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repro Med listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Earnings Share (0.26) | Revenue Per Share 0.674 | Quarterly Revenue Growth 0.215 | Return On Assets (0.14) |
The market value of Repro Med Systems is measured differently than its book value, which is the value of Repro that is recorded on the company's balance sheet. Investors also form their own opinion of Repro Med's value that differs from its market value or its book value, called intrinsic value, which is Repro Med's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repro Med's market value can be influenced by many factors that don't directly affect Repro Med's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repro Med's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repro Med is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repro Med's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.